Skip to main content

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Management to Participate in Two Upcoming Conferences

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced its participation in two March conferences: the 35th annual Roth Conference and the BIO-Europe Spring Conference. The Roth Conference is scheduled for March 12–14, 2023, in Dana Point, California. During this conference, the company will showcase its innovate gene therapy programs in oncology and diabetes as Genprex CFO Ryan Confer meets one-on-one with other conference attendees. In addition, several members of the Genprex management team are slated to attend the BIO-Europe Spring event, which is scheduled for March 20–22, and will be held in Switzerland. Company representatives will also be available to meet with other conference attendees at this event. “We are pleased to have members of our senior leadership team participate in these upcoming conferences as they offer an excellent opportunity to highlight the significant potential for our novel gene therapies to address unmet medical needs in oncology and diabetes,” said Genprex CEO Rodney Varner in the press release. “We look forward to providing an overview and update on our clinical development programs, including our phase 1 dose escalation portion of the Acclaim-1 phase 1/2 clinical trial of REQORSA(R) (quaratusugene ozeplasmid) in combination with Tagrisso(R) (osimertinib) to treat late-stage non-small cell lung cancer and our recent groundbreaking data from a nonhuman primate study evaluating our innovative gene therapy to treat type 1 diabetes presented at a global medical meeting.”

To view the full press release, visit https://ibn.fm/jbna2

About Genprex Inc. 

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, which currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which the company believes is the first systemic, gene-therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient in the body. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer. Both NSCLC clinical programs receiving a fast track designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.